Photo

Capricor Inks Commercialization Deal with Japanese Firm

Beverly Hills-based biotechnology company Capricor Therapeutics Inc. announced on Jan. 25 a major commercialization and distribution deal with a Japanese pharmaceutical company for its drug to treat the rare degenerative genetic disease Duchene muscular dystrophy.

• By Howard Fine
• February 7, 2022
SHARE